AZN Stock Down 20% in 6 Months: How to Play After Pipeline Setbacks
AstraZeneca AZN stock has declined 19.5% in the past six months despite solid underlying financial performance. A key reason…
Merck KGaA shares rise 1.7% after HSBC upgrades stock to Buy
Woman in mask and gown holding a test tube ©Adobe Stock Images Merck KGaA (NYSE:MRK) shares rose 1.7%…
Courts reject Medicare price negotiation lawsuits from Merck, AZ
Courts in Maryland and Washington, D.C., have rejected lawsuits by two pharma giants against the Centers for Medicare…
Top Healthcare Analyst: A $400 Billion AstraZeneca-Bristol Myers Deal Could “Cut Costs in a Big Way”
Quick Read BMY’s existing $2B cost-savings program and discounted forward P/E of ~10 make it an attractive AZN…
AstraZeneca Turns to China for Molecule That Might Top New Merck COPD Drug
AstraZeneca’s newest addition to its respiratory pipeline is an inhalable medication that could rival a Merck drug approved…